Risk is part of biopharmaceutical ...

Risk is part of biopharmaceutical unravelling Planning for commercialization typically starts after completion of phase 1 trials. If you wait until the completion of phase 3 to build a manufacturing facility, years of profitable sales will be misspent If you build a factory too early, you risk the possibility that the factory will be idle while waiting for proceeds approval. After all, in today's regulatory and economic climate, the unmatcheds of successfully bringing a fruit from discovery through clinical unravelling to commercial success are les than 1 in 100 Companies cannot be blamed for